Valuation: Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 6.42B 966M 861M 793M 720M 1.35B 91.93B 1.38B 9.48B 3.78B 48.15B 3.62B 3.55B 152B P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 5.58B 840M 749M 689M 626M 1.17B 79.93B 1.2B 8.24B 3.28B 41.87B 3.15B 3.08B 132B EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.2%
Yield 2024 *
-
Yield 2025 -
27/08 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
27/04 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
14/04 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/01 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
28/10/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
26/08/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
04/06/25 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
27/05/25 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25/04/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
18/03/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
15/03/25 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
13/03/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
11/03/25 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
1 day-2.37%
1 week-11.11%
Current month-21.10%
1 month-16.52%
6 months-20.22%
Current year-6.19%
1 week 2.87
Extreme 2.87
3.09
1 month 2.87
Extreme 2.87
3.78
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 26/12/2022
Corporate Officer/Principal 42 18/04/2018
Corporate Officer/Principal 40 23/05/2019
Director TitleAgeSince
Director/Board Member 40 14/03/2025
Director/Board Member 53 11/11/2022
Director/Board Member 42 11/11/2022
Date Insider Type Main position Quantity % Market Cap. Importance
2/7/25 Sell 587,500 0.0283%
2/7/25 Sell

Director

259,600 0.0125%
2/7/25 Sell 587,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
-2.37%-11.11%-10.00%+18.52% 987M
+6.63%+8.10%+67.50%+145.20% 1,148B
+1.53%+6.76%+47.22%+89.01% 652B
+1.68%+2.10%+27.80%+109.31% 505B
+0.73%+2.47%+53.85%+68.96% 384B
+3.83%-2.37%+68.14%+42.32% 348B
+2.38%+4.27%+33.81%+57.95% 294B
+2.26%+3.47%+5.21%+28.92% 264B
+1.97%+5.11%+57.74%+76.14% 244B
+4.03%+7.84%+40.49%+116.14% 197B
Average +0.96%+0.60%+39.18%+75.25% 403.81B
Weighted average by Cap. +1.07%+1.50%+49.56%+95.95%

Financials

2024 2025
Net sales 2.44B 367M 327M 301M 274M 512M 34.94B 523M 3.6B 1.44B 18.3B 1.38B 1.35B 57.85B 2.14B 321M 286M 264M 239M 448M 30.57B 457M 3.15B 1.26B 16.01B 1.2B 1.18B 50.62B
Net income 233M 34.99M 31.21M 28.73M 26.09M 48.83M 3.33B 49.85M 344M 137M 1.75B 131M 129M 5.52B 377M 56.67M 50.53M 46.52M 42.24M 79.07M 5.4B 80.72M 556M 222M 2.83B 213M 208M 8.93B
Net Debt -509M -76.48M -68.2M -62.79M -57.01M -107M -7.28B -109M -751M -299M -3.81B -287M -281M -12.06B -838M -126M -112M -103M -93.92M -176M -12B -179M -1.24B -493M -6.28B -473M -463M -19.86B
Projected Income Statement - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
29/10/26 CNY 2.880 -2.37% 117,068,100
28/10/26 CNY 2.950 +1.37% 142,305,478
27/10/26 CNY 2.910 -3.32% 118,166,342
26/10/26 CNY 3.010 -2.27% 136,398,152
23/10/26 CNY 3.080 +1.32% 203,469,986

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
  1. Stock Market
  2. Stocks
  3. 002437 Stock